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Abstract
microRNAs (miRNAs) are short non-coding RNAs regulating gene expression at the post-
transcriptional level by blocking translation or promoting cleavage of their target mRNAs.
Increasing evidence shows that miRNAs play central roles in gene transcription, signal
transduction and pathogenesis of human diseases. Diabetic nephropathy (DN) is a severe
microvascular complication that can lead to end-stage renal disease. Increased expansion
(hypertrophy) and accumulation of extracellular matrix (ECM) proteins such as collagen (fibrosis)
in the glomerular mesangium along with glomerular podocyte dysfunction are major features of
DN. Profiling of miRNAs and study of their functions in renal glomeruli can provide critical new
information to advance our knowledge of DN as well as other kidney diseases and thereby
uncover much needed new therapeutic targets. In this review, we summarize the biogenesis of
miRNAs and their functions in the glomerulus, with particular emphasis on glomerular mesangial
cells and podocytes related to the pathogenesis of DN.
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Introduction
The kidney is a relatively small but very important organ due to its innumerable functions in
various critical physiological processes including blood pressure regulation, maintenance of
acid-base and electrolyte balance, and filtration of the blood to remove wastes. As such,
renal dysfunction can lead to several diseases including diabetic nephropathy (DN), a
debilitating microvascular complication of diabetes that can result in end-stage renal disease.
Furthermore, patients with DN are highly susceptible to macrovascular diseases such as
atherosclerosis, hypertension and stroke and there is a close correlation between chronic
kidney disease (CKD) and cardiovascular disease (CVD) [1].
The kidneys are bean-shaped organs (Figure1A) with each being surrounded by a
transparent fibrous renal capsule. There are two key regions in the kidney, the outer renal
cortex and the inner medulla. Nephrons, the urine producing structural and functional units
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of the kidneys, span the cortex and medulla. Each nephron consists of a renal corpuscle
composed of a capillary tuft (the glomerulus), surrounded by the glomerular (Bowman’s)
capsule and a tubule. Glomeruli are located in the cortex and are the primary sites of
filtration (Figure 1B). Blood enters into the glomerulus via the afferent arteriole, circulates
inside and exits via the efferent arteriole (Figure 1C). Glomeruli are connected to the
proximal tubule which eventually leads to the collecting tubule via the distal tubule and
many loops and turns. Podocytes or visceral epithelial cells wrap around the glomerular
capillaries and play critical roles in the regulation of filtration. Podocyte dysfunction can
lead to proteinuria as seen in DN.
Hypertrophy and expansion in the glomerular mesangium and tubular compartments, along
with podocyte dysfunction and accumulation of ECM proteins (fibrosis), are major features
of DN, and contribute to renal failure in diabetes mellitus [2-3]. Enhanced expression of
Transforming growth factor-beta1 (TGF-β) in renal cells plays a key role in glomerular
mesangial hypertrophy and fibrosis under diabetic conditions by inducing the expression of
ECM proteins such as collagen and fibronectin [2-9]. Although an antibody against TGF-β
was effective to some extent in animal models of DN [10] and some trials targeting TGF-β
itself and with antifibrotic drugs are ongoing [11], such approaches could have limitations
due to the multifunctional nature of TGF-β. Furthermore, while several studies have
investigated the signaling mechanisms leading to DN [2], the molecular mechanisms are still
not well understood. A further investigation of molecular events downstream of TGF-β
signaling in renal cells can uncover new targets to more effectively prevent or treat DN.
Interesting reports showed that mice with podocyte-specific deletion of Dicer or Drosha, key
enzymes involved in microRNA (miRNA) biogenesis, display progressive glomerular and
tubular damage along with proteinuria and other podocyte defects [12-15]. Mice with Dicer
deletion in the entire nephron lineage showed defects in kidney development [16-17].
miRNAs function in kidney development even in frogs [18]. Furthermore, of particular
interest are reports demonstrating that a cluster of miRNAs are highly expressed in the
kidney, and that there are key differences in the miRNA expression profile in renal cortex
versus medulla [19-20]. In recent years, the functional roles of key miRNAs in glomerular
cells have been extensively studied in TGF-β actions and diabetic kidney disease [5, 8,
21-26]. These results suggest that specific miRNAs in glomerular cells such as podocytes,
mesangial and endothelial cells, as well as other renal cells may have critical biological
functions and could therefore be exploited as novel targets for kidney diseases.
microRNAs
miRNAs are short (~21 nucleotides) non-coding RNAs that regulate gene expression
generally by translational inhibition or cleavage of their target RNAs (Figure 2)[27-28].
miRNAs are initially transcribed as long primary miRNAs (Pri-miRNAs) which are
processed to a stem-loop (hairpin) structure fragment termed precursor-miR (Pre-miRNA) in
the nucleus by an RNase III enzyme, Drosha, in collaboration with the double strand RNA
binding protein, DGCR8[27-28]. For certain miRNAs, this process can also be enhanced by
Smads in response to TGF-β or bone morphogenetic proteins (BMPs) [29-30], or by
p53[31]. Pre-miRNAs (~70 nucleotides) are then exported to the cytoplasm by Exportin-5
and further cleaved to miRNA duplexes by another RNase III family enzyme, Dicer [27-28].
The miRNA duplexes are then unwound and one strand, termed “mature miRNA” or guide
strand, which has complementarity to target mRNAs, is loaded into the RNA-induced
silencing complex (RISC) which contains Argonaute 2 (Ago2), Dicer and TRBP proteins
[27-28]. If the complementarity of miRNAs to target RNAs is perfect, RISC cleaves the
target mRNA (classical RNA interference, RNAi). However, most miRNAs and their target
RNAs have some mismatches and RISC induces translational repression of target genes by
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hybridizing of miRNAs to their 3′ untranslated region (UTR) [27-28]. Although complete
complementarity is not required for miRNA-mediated regulation of a target transcript, the
“seed sequence”, namely seven key nucleotides of the miRNA 5′ sequence, is critical.
miRNAs inhibit the initiation and elongation steps of translation to reduce protein
expression [27-28]. They can also repress gene expression by sequestering targeted mRNAs
to cytoplasmic mRNA processing bodies (P-bodies) for degradation. In addition to their role
in such post-transcriptional repression, miRNAs are also implicated in transcriptional gene
silencing by targeting the promoter regions [32]. Therefore, miRNAs regulate gene
expression through translational repression, target mRNA degradation or transcriptional
inhibition. There is increasing interest in miRNAs since they can affect more than 60% of
protein-coding genes [28]. Furthermore, evidence shows that they are dysregulated in
various diseases and affect the expression of several disease related genes. Moreover, these
small RNAs have now been identified in plasma and urine of human patients and animal
models [33-35]. Thus miRNAs are attractive candidate biomarkers and therapeutic targets
for human diseases such as DN.
miRNAs regulating fibrosis in glomerular mesangial cells and other renal
cells
Among the miRNAs highly expressed in the kidney [19-20], several key miRNAs
(miR-192, miR-200b, miR-200c, miR-216a and miR-217) were found to be higher in renal
glomeruli of mouse models of diabetes [type 1(streptozotocin (STZ)-induced) and type2 (db/
db)] compared to the corresponding controls[5, 8, 22-23, 25-26]. Some or all of these
miRNAs were also increased by TGF-β or high glucose (HG) in mouse mesangial cells
(MMC) and in human MC [22-26]. Although in vitro treatments do not fully mimic DN in
vivo, similarities in the profile of induced miRNAs have been noted most likely because
diabetic stimuli and factors associated with DN like HG, growth factors and advanced
glycation end products can induce TGF-β in renal cells. Furthermore, increased expression
of these miRNAs have also been reported in kidneys from patients with hypertensive
nephrosclerosis, IgA nephropathy and lupus nephritis[36-38], as well as some other animal
models of kidney injury[22, 39-41].
Interestingly, miR-192 targets Zeb1 and Zeb2 which are now widely recognized as general
E-box repressors [42-44], and increases Collagen type I alpha2 (Col1a2) gene expression in
MMC, demonstrating that increased miR-192 in diabetic conditions induces fibrosis by
inhibiting E-box repressors (Figure 1F)[8]. Other MC miRNAs have also been implicated in
renal fibrosis associated with DN. miR-377 was shown to induce fibronectin (ECM protein)
expression via downregulation of manganese superoxide dismutase and p21-activated kinase
in MCs(Figure 1F)[25]. Upregulation of miR-21 by diabetic conditions or TGF-β was also
associated with MC and renal fibrosis or injury [45-48], although a report showed that
miR-21 levels were decreased in glomeruli from db/db mice [49]. Down-regulation of the
miR-29 family, which targets various collagens in multiple cell types, was reported to
induce fibrosis in hypertensive and other renal injury models (Figure 1F)[50-52].
The miR-200 family members are separated into two clusters based on genomic structures.
They are located in the introns of their host RNAs and also regulated by the miR-192 targets
Zeb1/2 through E-boxes in the promoter of the host gene [23, 53-54]. miR-200 family also
targets Zeb1/2 at their upstream E-boxes to auto-upregulate their own expression and can
thereby accelerate the signaling pathways leading to collagen expression and renal
fibrosis[23].
In MC, diabetic conditions induce TGF-β1 through several transcriptional mechanisms
including binding of E-box activators, Upstream Stimulatory Factors USFs, to an E-box
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element in the TGF-β1 promoter [23, 55-57]. Interestingly, TGF-β1 gene itself is
upregulated by TGF-β1 in MMC through the same promoter E-box element and recent
evidence shows this autoregulation is also mediated by the E-box repressors Zeb1/2 targeted
by the miRNA circuit, miR-192 to miR-200b/c [23]. miR-200a/c were reported to be
induced by TGF-β or BMPs in pulmonary smooth muscle cells[29]. miR-200b was
upregulated not only in glomeruli from db/db mice but also in endothelial cells and
podocytes treated with HG [22-23]. miR-200 family was reported to be both increased and
decreased in Unilateral ureter obstruction (UUO) mouse model of kidney fibrosis[51, 58].
Interestingly, Wang et al. reported that in mouse DN and tubular epithelial cells treated with
TGF-β there is a down-regulation of miR-200a which targets TGF-β receptor 2, suggesting
another accelerating signaling loop via miR-200a [59]. These studies also demonstrate key
cell-specific differences in miRNA-200 responses under disease states.
miR-216a and miR-217 are located in the second intron of the mouse non-coding RNA
RP23-298H6.1-001(RP23) and their expression depends on this host non-coding RNA[5].
RP23 expression is regulated by the E-box cluster in its promoter and by miR-192 through
Zeb1/2, suggesting signal amplification via miRNAs (Figure 1F)[5]. miR-216a can also
increase collagen expression by another parallel mechanism involving the inhibition of
Ybx1, an RNA binding protein and a component of P-bodies [26]. Taken together, miRNA
circuits initiated by miR-192 can amplify and fine-tune downstream pathways to further
augment collagen expression and mesangial fibrosis related to the pathogenesis of DN [5, 8,
23, 26].
miRNAs in glomerular mesangial cell hypertrophy
Renal glomerular expansion (hypertrophy) is a major feature of DN and contributes to
kidney failure. Figure 1 D&E show representative examples demonstrating that glomeruli
from diabetic mice are significantly larger than those from non-diabetic animals. Akt kinase
activation is related to cancer development and diabetes by regulating several downstream
cellular targets such as mTOR, GSK-3β and FoxO proteins [60]. Since these downstream
targets are major regulators of protein synthesis, apoptosis and cell survival, Akt activation
is a major mediator of cellular hypertrophy under disease conditions. One report suggested
that TGF-β activates phosphatidylinositol-3-kinase (PI3K)/Akt pathway via direct physical
interaction of the TGF-β receptor and PI3K [61]. However, the mechanisms, especially
long-term chronic activation of Akt by TGF-β were not fully understood.
As described above, two miRNAs (miR-216a and miR-217) were upregulated in MMC
treated with TGF-β and in glomeruli from diabetic mice. Interestingly, both these miRNAs
target phosphatase and tensin homologue (PTEN), an upstream inhibitor of Akt,
demonstrating that these two miRNAs upregulated by TGF-β can activate Akt and
downstream signaling through inhibition of PTEN (Figure 1F)[5]. This is also supported by
data showing that miR-21 targets PTEN, and thereby contributes to renal pathology [46].
Thus, Akt activation by miRNA circuits induced by TGF-β could be a novel mechanism for
mesangial hypertrophy in diabetes. In addition, the miR-200 family has been reported to
control PI3K signaling by targeting Fog2, an inhibitor of PI3K[62]. As PI3K/Akt activation
in diabetic kidney cells induces hypertrophy and fibrosis [4-6, 26], upregulation of miR-200
family members may also activate Akt through inhibition of Fog2 to promote mesangial
hypertrophy.
Interestingly, p53 and miR-192 regulate each other to form another signaling loop [63-65].
p53 regulates multiple genes related to cell cycle, such as p21 (cyclin-dependent kinase
inhibitor), suggesting that inhibition of cell cycle progression by miRNA actions may induce
hypertrophy in glomeruli. Since Eukaryotic translation Elongation factor 1-alpha 1 (EF1α)
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is also upregulated by p53[66], increased levels of EF1α might enhance protein synthesis
and hypertrophy in the diabetic glomeruli. Furthermore, recent reports showed that miR-200
family is also regulated by p53 [67-68].
Therefore, these miRNA-mediated amplifying circuits encompassing miR-192, miR-200
family, miR-216a and miR-217 in conjunction with other miRNAs can serve as signal
modulators to accelerate fibrosis and hypertrophy in TGF-β-mediated chronic diseases like
DN (Figure 1F).
miRNAs in glomerular endothelial cells and podocytes
As noted earlier, mice with podocyte-specific deletion of Drosha or Dicer displayed severe
renal phenotype and proteinuria[12-15], suggesting a significant role for miRNAs in
podocytes. It was reported that miR-93 levels were lower in glomeruli obtained from
diabetic db/db mice relative to control mice, and also in HG treated podocytes and renal
microvascular endothelial cells. This corresponded to increases in Vascular Endothelial
Growth Factor-A, a target of miR-93 (Figure 1G)[24]. miR-200b and miR-29c were
upregulated along with miR-192 in glomeruli from db/db mice, as well as in endothelial
cells and podocytes treated with HG. MiR-29c activates Rho kinase by targeting Spry1 and
contributes to DN (enhanced ECM accumulation and podocyte apoptosis)[22]. db/db mice
injected with 2′-O-methyl antisense oligonucleotides targeting miR-29c showed reduction
in the progression of DN [22].
Regulation of miR-192 by TGF-β and in other models of kidney injury
There is much interest in evaluating the processes regulating the expression of miRNAs
under disease conditions. Two major mechanisms may be involved in TGF-β induced
upregulation of miR-192. One is the classical mechanism through Smad3[40] and another
involving p53[63-65], since the miR-192 promoter has Smad and p53 binding sequences.
Subsequently, miR-192 can in turn induce miR-200b/c probably through E-boxes in their
promoters [23, 53-54].
However, it is well known that TGF-β effects are cell-type specific and context dependent.
Evidence shows that the expression of miR-192 and miR-200 family members are decreased
in cancer or kidney-derived epithelial cell lines treated with TGF-β[54, 69-70]. In the
NRK52E epithelial cell line, one report showed that miR-192 levels were increased at 1-24
hr [40], while another showed that miR-192 levels were decreased by TGF-β at 3 days[71].
It is possible that there is a biphasic regulation in which miR-192 and 200 family may be
induced by TGF-β1 at early time points (6-24 hours) but downregulated later, although such
a regulation in vivo in DN is more difficult to envision. Since accumulation of ECM
proteins in fibrotic events in MC and tubular cells are well-established features of DN [2],
the upregulation of collagen by TGF-β1 via increase in miR-192 and miR-200b in MC could
be a key feature of DN and potentially more relevant during the early stages of diabetic
kidney injury. Furthermore, diabetes affects multiple cells in glomeruli as well as other renal
compartments and can regulate a spectrum of miRNAs with cell-type specific targets and
responses related to DN. Clearly, such miRNA profiles can vary in other models of renal
injury.
As described above, miR-192 is regulated by Smad3 and p53 [40, 64-65]. Mutations in p53
and Smad genes have been observed in cancer cell lines and other immortalized cell lines.
Mutant p53 changes the response to TGF-β via Smad interaction[72]. Kidney injury and
fibrosis were ameliorated in p53 or Smad3 knockout mice[40, 73-74]. Recent papers also
showed that p53 is a major regulator of epithelial to mesenchymal transition in cancer
through miR-192 and miR-200 family [67-68]. Therefore, p53 and Smad genes may be key
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factors dictating TGF-β responses and hence the effects of TGF-β on miR-192, miR-200
family and other miRNAs in primary MC may be different from those reported in cancer or
immortalized kidney cell lines. This might account for some of the cell-type discrepancies in
TGF-β1 responses, as well as for the disease specific effects of miRNAs.
A recent report also showed that low-dose paclitaxel, a cancer drug, could prevent renal
fibrosis in the remnant kidney model by down-regulating miR-192 [41]. In addition, in
models of ischemia reperfusion, better survival was noted in tubular specific Dicer knockout
mice that had lower levels of miR-192, and lower miR-192 was also noted in other studies
[75-76]. Although there are both similarities and discrepancies in miRNA profiles observed
in various models of renal injury, inhibition of miR-192 seems beneficial in several models
as mentioned above [41, 75].
miRNAs as biomarkers and therapeutic targets
The rapid recent technological advances in miRNA detection and quantification, including
microarrays, quantitative PCRs and next generation sequencing, have spurred tremendous
interest in developing miRNAs as therapeutic targets and potential biomarkers for human
diseases. Recent reports showed that circulating miRNAs in blood are sensitive biomarkers
for cancer, tissue injury and heart failure[33-34]. Levels of miRNAs in the urinary sediment
of patients with IgA nephropathy have been examined [35]. These results support the notion
that profiling circulating miRNAs in biofluids could lead to the identification of sensitive
and precise diagnostic biomarkers of various human diseases in general and renal disorders
in particular. Since miRNAs can be quantitatively detected in urine and plasma, they could
serve as new biomarkers for the early detection of diabetic renal injury, a major goal for the
clinical nephrologist. Clinical trials with anti-miRNAs for hepatitis C and other diseases are
already being developed [77-78]. Thus, it is possible that anti-miRNA therapies to target key
circulating or locally expressed miRNAs could also be developed for the treatment of acute
and chronic renal disorders. Since miR-192 can control several renal miRNAs related to DN,
it is a good candidate target to evaluate for DN treatment. Recently, specific and efficient
reduction of miR-192 was observed in vivo in normal mice injected with locked nucleic acid
(LNA)-modified antimiR-192 (LNA-antimiR-192)[5]. LNA-antimiR-192 also reduced
downstream miRNAs (miR-216a, miR-217 and miR-200 family) and functional indices of
renal fibrosis and hypertrophy, such as collagens and TGF-β1 expression and Akt activation
in these mice, similar to the effects in cultured MMC[5, 23]. Apart from miR-192, targeted
inhibition or overexpression of other key renal miRNAs such as miR-200 family members,
miR-29c, miR-29b or miR-21 have shown promise in in vitro and in vivo models of DN and
other renal diseases, as described earlier. Given the tremendous activity in this field in recent
years, several other renal miRNAs are expected to be identified in the near future that can
also be evaluated as diagnostic biomarkers or potential therapeutic targets.
Closing Remarks
Renal glomeruli are relatively small structures but are powerhouses with critical roles in
kidney function. Emerging evidence shows that even tinier molecules like miRNAs can play
significant modulatory roles in the biology and pathology of glomerular function and renal
pathogenesis. Major future advances are anticipated in this field including the identification
of additional miRNA modulators of various renal functions, as well as development of
miRNA based biomarkers and therapies for various renal diseases.
Acknowledgments
The authors gratefully acknowledge grant support from the National Institutes of Health (NIDDK and NHLBI) and
the Juvenile Diabetes Research Foundation.
Kato et al. Page 6
Exp Cell Res. Author manuscript; available in PMC 2013 May 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
References
[1]. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic
renal disease. Am J Kidney Dis. 1998; 32:S112–119. [PubMed: 9820470]
[2]. Brosius FC, Khoury CC, Buller CL, Chen S. Abnormalities in signaling pathways in diabetic
nephropathy. Expert Rev Endocrinol Metab. 2010; 5:51–64. [PubMed: 20224802]
[3]. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis. 1993; 22:736–
744. [PubMed: 8238022]
[4]. Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, Hu MC, Reddy MA, Natarajan R. Role of
the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism
related to diabetic kidney disease. J Am Soc Nephrol. 2006; 17:3325–3335. [PubMed: 17082237]
[5]. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, Gunn A, Nakagawa Y, Shimano H,
Todorov I, Rossi JJ, Natarajan R. TGF-beta activates Akt kinase through a microRNA-dependent
amplifying circuit targeting PTEN. Nat Cell Biol. 2009; 11:881–889. [PubMed: 19543271]
[6]. Mahimainathan L, Das F, Venkatesan B, Choudhury GG. Mesangial cell hypertrophy by high
glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes. 2006; 55:2115–
2125. [PubMed: 16804083]
[7]. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming
growth factor-beta as a key mediator. Diabetes. 1995; 44:1139–1146. [PubMed: 7556948]
[8]. Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, Natarajan R. MicroRNA-192 in diabetic
kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-
box repressors. Proc Natl Acad Sci U S A. 2007; 104:3432–3437. [PubMed: 17360662]
[9]. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming
growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad
Sci U S A. 1993; 90:1814–1818. [PubMed: 7680480]
[10]. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S,
McGowan TA, Sharma K. Long-term prevention of renal insufficiency, excess matrix gene
expression, and glomerular mesangial matrix expansion by treatment with monoclonal
antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A.
2000; 97:8015–8020. [PubMed: 10859350]
[11]. Decleves AE, Sharma K. New pharmacological treatments for improving renal outcomes in
diabetes. Nat Rev Nephrol. 2010; 6:371–380. [PubMed: 20440278]
[12]. Zhdanova O, Srivastava S, Di L, Li Z, Tchelebi L, Dworkin S, Johnstone DB, Zavadil J, Chong
MM, Littman DR, Holzman LB, Barisoni L, Skolnik EY. The inducible deletion of Drosha and
microRNAs in mature podocytes results in a collapsing glomerulopathy. Kidney Int. 2011;
80:719–730. [PubMed: 21544061]
[13]. Harvey SJ, Jarad G, Cunningham J, Goldberg S, Schermer B, Harfe BD, McManus MT, Benzing
T, Miner JH. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes
glomerular disease. J Am Soc Nephrol. 2008; 19:2150–2158. [PubMed: 18776121]
[14]. Shi S, Yu L, Chiu C, Sun Y, Chen J, Khitrov G, Merkenschlager M, Holzman LB, Zhang W,
Mundel P, Bottinger EP. Podocyte-selective deletion of dicer induces proteinuria and
glomerulosclerosis. J Am Soc Nephrol. 2008; 19:2159–2169. [PubMed: 18776119]
[15]. Ho J, Ng KH, Rosen S, Dostal A, Gregory RI, Kreidberg JA. Podocyte-specific loss of functional
microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol. 2008; 19:2069–
2075. [PubMed: 18832437]
[16]. Nagalakshmi VK, Ren Q, Pugh MM, Valerius MT, McMahon AP, Yu J. Dicer regulates the
development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int.
2011; 79:317–330. [PubMed: 20944551]
[17]. Ho J, Pandey P, Schatton T, Sims-Lucas S, Khalid M, Frank MH, Hartwig S, Kreidberg JA. The
Pro-Apoptotic Protein Bim Is a MicroRNA Target in Kidney Progenitors. J Am Soc Nephrol.
2011; 22:1053–1063. [PubMed: 21546576]
[18]. Wessely O, Agrawal R, Tran U. MicroRNAs in kidney development: lessons from the frog. RNA
Biol. 2010; 7:296–299. [PubMed: 20458188]
Kato et al. Page 7
Exp Cell Res. Author manuscript; available in PMC 2013 May 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
[19]. Sun Y, Koo S, White N, Peralta E, Esau C, Dean NM, Perera RJ. Development of a micro-array
to detect human and mouse microRNAs and characterization of expression in human organs.
Nucleic Acids Res. 2004; 32:e188. [PubMed: 15616155]
[20]. Tian Z, Greene AS, Pietrusz JL, Matus IR, Liang M. MicroRNA-target pairs in the rat kidney
identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 2008;
18:404–411. [PubMed: 18230805]
[21]. Kato M, Arce L, Natarajan R. MicroRNAs and their role in progressive kidney diseases. Clin J
Am Soc Nephrol. 2009; 4:1255–1266. [PubMed: 19581401]
[22]. Long J, Wang Y, Wang W, Chang BH, Danesh FR. MicroRNA-29c is a signature microRNA
under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown
prevents progression of diabetic nephropathy. J Biol Chem. 2011; 286:11837–11848. [PubMed:
21310958]
[23]. Kato M, Arce L, Wang M, Putta S, Lanting L, Natarajan R. A microRNA circuit mediates
transforming growth factor-beta1 autoregulation in renal glomerular mesangial cells. Kidney Int.
2011; 80:358–368. [PubMed: 21389977]
[24]. Long J, Wang Y, Wang W, Chang BH, Danesh FR. Identification of microRNA-93 as a novel
regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem. 2010;
285:23457–23465. [PubMed: 20501654]
[25]. Wang Q, Wang Y, Minto AW, Wang J, Shi Q, Li X, Quigg RJ. MicroRNA-377 is up-regulated
and can lead to increased fibronectin production in diabetic nephropathy. Faseb J. 2008;
22:4126–4135. [PubMed: 18716028]
[26]. Kato M, Wang L, Putta S, Wang M, Yuan H, Sun G, Lanting L, Todorov I, Rossi JJ, Natarajan
R. Posttranscriptional upregulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-
{beta}-induced collagen expression in kidney cells. J Biol Chem. 2010; 285:34004–34015.
[PubMed: 20713358]
[27]. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol.
2010; 11:252–263. [PubMed: 20216554]
[28]. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136:215–233.
[PubMed: 19167326]
[29]. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA
sequence to promote microRNA maturation by Drosha. Mol Cell. 2010; 39:373–384. [PubMed:
20705240]
[30]. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated
microRNA maturation. Nature. 2008; 454:56–61. [PubMed: 18548003]
[31]. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of
microRNA processing by p53. Nature. 2009; 460:529–533. [PubMed: 19626115]
[32]. Kim DH, Saetrom P, Snove O Jr. Rossi JJ. MicroRNA-directed transcriptional gene silencing in
mammalian cells. Proc Natl Acad Sci U S A. 2008; 105:16230–16235. [PubMed: 18852463]
[33]. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A,
Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt
DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as
stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105:10513–
10518. [PubMed: 18663219]
[34]. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM.
MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010; 106:1035–1039.
[PubMed: 20185794]
[35]. Wang G, Kwan BC, Lai FM, Chow KM, Kam-Tao Li P, Szeto CC. Expression of microRNAs in
the urinary sediment of patients with IgA nephropathy. Dis Markers. 2010; 28:79–86. [PubMed:
20364043]
[36]. Wang G, Kwan BC, Lai FM, Choi PC, Chow KM, Li PK, Szeto CC. Intrarenal Expression of
miRNAs in Patients With Hypertensive Nephrosclerosis. Am J Hypertens. 2010; 23:78–84.
[PubMed: 19910931]
Kato et al. Page 8
Exp Cell Res. Author manuscript; available in PMC 2013 May 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
[37]. Wang G, Kwan BC, Lai FM, Choi PC, Chow KM, Li PK, Szeto CC. Intrarenal expression of
microRNAs in patients with IgA nephropathy. Lab Invest. 2010; 90:98–103. [PubMed:
19901913]
[38]. Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y. Comprehensive analysis of microRNA
expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int. 2009; 29:749–
754. [PubMed: 18998140]
[39]. Wang XX, Jiang T, Shen Y, Caldas Y, Miyazaki-Anzai S, Santamaria H, Urbanek C, Solis N,
Scherzer P, Lewis L, Gonzalez FJ, Adorini L, Pruzanski M, Kopp JB, Verlander JW, Levi M.
Diabetic Nephropathy is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by
Farnesoid X Receptor Activation in a Type 1 Diabetes Model. Diabetes. 2010; 59:2916–2927.
[PubMed: 20699418]
[40]. Chung AC, Huang XR, Meng X, Lan HY. miR-192 Mediates TGF-{beta}/Smad3-Driven Renal
Fibrosis. J Am Soc Nephrol. 2010; 21:1317–1325. [PubMed: 20488955]
[41]. Sun L, Zhang D, Liu F, Xiang X, Ling G, Xiao L, Liu Y, Zhu X, Zhan M, Yang Y, Kondeti VK,
Kanwar YS. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-
regulating miR-192. Journal of Pathology. 2011 in press.
[42]. Sekido R, Murai K, Funahashi J, Kamachi Y, Fujisawa-Sehara A, Nabeshima Y, Kondoh H. The
delta-crystallin enhancer-binding protein delta EF1 is a repressor of E2-box-mediated gene
activation. Mol Cell Biol. 1994; 14:5692–5700. [PubMed: 8065305]
[43]. Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS, Tylzanowski P, Nelles L, Wuytens G,
Su MT, Bodmer R, Smith JC, Huylebroeck D. SIP1, a novel zinc finger/homeodomain repressor,
interacts with Smad proteins and binds to 5′-CACCT sequences in candidate target genes. J Biol
Chem. 1999; 274:20489–20498. [PubMed: 10400677]
[44]. Ponticos M, Partridge T, Black CM, Abraham DJ, Bou-Gharios G. Regulation of collagen type I
in vascular smooth muscle cells by competition between Nkx2.5 and deltaEF1/ZEB1. Mol Cell
Biol. 2004; 24:6151–6161. [PubMed: 15226419]
[45]. Zarjou A, Yang S, Abraham E, Agarwal A, Liu G. Identification of a microRNA signature in
renal fibrosis: Role of miR-21. Am J Physiol Renal Physiol. 2011 in press.
[46]. Dey N, Das F, Mariappan MM, Mandal CC, Ghosh-Choudhury N, Kasinath BS, Choudhury GG.
MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal
cell pathology in diabetes. J Biol Chem. 2011; 286:25586–25603. [PubMed: 21613227]
[47]. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY. Smad3-Mediated Upregulation of miR-21
Promotes Renal Fibrosis. J Am Soc Nephrol. 2011; 22:1668–1681. [PubMed: 21852586]
[48]. Denby L, Ramdas V, McBride MW, Wang J, Robinson H, McClure J, Crawford W, Lu R,
Hillyard DZ, Khanin R, Agami R, Dominiczak AF, Sharpe CC, Baker AH. miR-21 and miR-214
are consistently modulated during renal injury in rodent models. Am J Pathol. 2011; 179:661–
672. [PubMed: 21704009]
[49]. Zhang Z, Peng H, Chen J, Chen X, Han F, Xu X, He X, Yan N. MicroRNA-21 protects from
mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 2009;
583:2009–2014. [PubMed: 19450585]
[50]. Du B, Ma LM, Huang MB, Zhou H, Huang HL, Shao P, Chen YQ, Qu LH. High glucose down-
regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 2010; 584:811–
816. [PubMed: 20067797]
[51]. Qin W, Chung AC, Huang XR, Meng XM, Hui DS, Yu CM, Sung JJ, Lan HY. TGF-beta/Smad3
signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol. 2011; 22:1462–1474.
[PubMed: 21784902]
[52]. Liu Y, Taylor NE, Lu L, Usa K, Cowley AW Jr. Ferreri NR, Yeo NC, Liang M. Renal medullary
microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes.
Hypertension. 2010; 55:974–982. [PubMed: 20194304]
[53]. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ. A double-
negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-
mesenchymal transition. Cancer Res. 2008; 68:7846–7854. [PubMed: 18829540]
Kato et al. Page 9
Exp Cell Res. Author manuscript; available in PMC 2013 May 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
[54]. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal
repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in
cancer cells. EMBO Rep. 2008; 9:582–589. [PubMed: 18483486]
[55]. Zhu Y, Casado M, Vaulont S, Sharma K. Role of upstream stimulatory factors in regulation of
renal transforming growth factor-beta1. Diabetes. 2005; 54:1976–1984. [PubMed: 15983197]
[56]. Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE. Glucose up-regulates
thrombospondin 1 gene transcription and transforming growth factor-beta activity through
antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J
Biol Chem. 2004; 279:34311–34322. [PubMed: 15184388]
[57]. Weigert C, Brodbeck K, Sawadogo M, Haring HU, Schleicher ED. Upstream stimulatory factor
(USF) proteins induce human TGF-beta1 gene activation via the glucose-response
element-1013/-1002 in mesangial cells: up-regulation of USF activity by the hexosamine
biosynthetic pathway. J Biol Chem. 2004; 279:15908–15915. [PubMed: 14757763]
[58]. Oba S, Kumano S, Suzuki E, Nishimatsu H, Takahashi M, Takamori H, Kasuya M, Ogawa Y,
Sato K, Kimura K, Homma Y, Hirata Y, Fujita T. miR-200b precursor can ameliorate renal
tubulointerstitial fibrosis. PLoS One. 2010; 5:e13614. [PubMed: 21049046]
[59]. Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, Jandeleit-Dahm K,
Burns WC, Thomas MC, Cooper ME, Kantharidis P. miR-200a Prevents renal fibrogenesis
through repression of TGF-beta2 expression. Diabetes. 2011; 60:280–287. [PubMed: 20952520]
[60]. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129:1261–
1274. [PubMed: 17604717]
[61]. Yi JY, Shin I, Arteaga CL. Type I transforming growth factor beta receptor binds to and activates
phosphatidylinositol 3-kinase. J Biol Chem. 2005; 280:10870–10876. [PubMed: 15657037]
[62]. Hyun S, Lee JH, Jin H, Nam J, Namkoong B, Lee G, Chung J, Kim VN. Conserved MicroRNA
miR-8/miR-200 and its target USH/FOG2 control growth by regulating PI3K. Cell. 2009;
139:1096–1108. [PubMed: 20005803]
[63]. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr.
Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M,
Aqeilan RI, Palumbo A, Croce CM. Downregulation of p53-inducible microRNAs 192, 194, and
215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell.
2010; 18:367–381. [PubMed: 20951946]
[64]. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Orntoft TF, Andersen CL,
Dobbelstein M. p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle
Arrest. Cancer Res. 2008; 68:10094–10104. [PubMed: 19074875]
[65]. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, Jackson AL, Carleton MO,
Linsley PS, Cleary MA, Chau BN. Coordinated regulation of cell cycle transcripts by p53-
Inducible microRNAs, miR-192 and miR-215. Cancer Res. 2008; 68:10105–10112. [PubMed:
19074876]
[66]. Kato MV, Sato H, Nagayoshi M, Ikawa Y. Upregulation of the elongation factor-1alpha gene by
p53 in association with death of an erythroleukemic cell line. Blood. 1997; 90:1373–1378.
[PubMed: 9269753]
[67]. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh
SS, Alder H, Liu CG, Dejean A, Croce CM. p53 regulates epithelial-mesenchymal transition
through microRNAs targeting ZEB1 and ZEB2. J Exp Med. 2011; 208:875–883. [PubMed:
21518799]
[68]. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH,
Liu M, Chen CT, Yu D, Hung MC. p53 regulates epithelial-mesenchymal transition and stem cell
properties through modulating miRNAs. Nat Cell Biol. 2011; 13:317–323. [PubMed: 21336307]
[69]. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall
Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition
by targeting ZEB1 and SIP1. Nat Cell Biol. 2008; 10:593–601. [PubMed: 18376396]
[70]. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial
phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev.
2008; 22:894–907. [PubMed: 18381893]
Kato et al. Page 10
Exp Cell Res. Author manuscript; available in PMC 2013 May 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
[71]. Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A, Saleem M,
Goodall GJ, Twigg SM, Cooper ME, Kantharidis P. E-cadherin expression is regulated by
miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming
growth factor-beta. Diabetes. 2010; 59:1794–1802. [PubMed: 20393144]
[72]. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S,
Rondina MB, Guzzardo V, Parenti AR, Rosato A, Bicciato S, Balmain A, Piccolo S. A Mutant-
p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009; 137:87–
98. [PubMed: 19345189]
[73]. Zhou L, Fu P, Huang XR, Liu F, Lai KN, Lan HY. Activation of p53 promotes renal injury in
acute aristolochic acid nephropathy. J Am Soc Nephrol. 2010; 21:31–41. [PubMed: 19892935]
[74]. Bhatt K, Zhou L, Mi QS, Huang S, She JX, Dong Z. MicroRNA-34a is induced via p53 during
cisplatin nephrotoxicity and contributes to cell survival. Mol Med. 2010; 16:409–416. [PubMed:
20386864]
[75]. Wei Q, Bhatt K, He HZ, Mi QS, Haase VH, Dong Z. Targeted deletion of Dicer from proximal
tubules protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2010; 21:756–761.
[PubMed: 20360310]
[76]. Godwin JG, Ge X, Stephan K, Jurisch A, Tullius SG, Iacomini J. Identification of a microRNA
signature of renal ischemia reperfusion injury. Proc Natl Acad Sci U S A. 2010; 107:14339–
14344. [PubMed: 20651252]
[77]. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjarn M, Hansen
HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S. LNA-mediated
microRNA silencing in non-human primates. Nature. 2008; 452:896–899. [PubMed: 18368051]
[78]. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S,
Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus
infection. Science. 2010; 327:198–201. [PubMed: 19965718]
Kato et al. Page 11
Exp Cell Res. Author manuscript; available in PMC 2013 May 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Functions of miRNAs in glomeruli related to the progression of diabetic nephropathy
A,B,D,E) Representative examples of Hematoxylin and Eosin (H&E) staining of mouse
kidney (C57/Bl6 strain) sections. A) Low magnification picture of whole kidney (courtesy
of Dr. Ivan Todorov). Scale bar indicates 1mm. B) High magnification power picture of
kidney cortex section. Arrows indicate glomeruli. Scale bar indicates 100μm. C) Schematic
structure of the glomerulus. Mesangial cells, Podocytes and Endothelial cells are shown in
blue, green and gray, respectively. D & E) Higher power representative picture of a
glomerulus from normal non-diabetic mouse and from streptozotocin-injected mouse (model
of type 1 diabetes), respectively. Scale bar indicates 20μm. F & G) Signal transduction
pathways mediated by miRNAs in mesangial cells and podocytes related to the progression
of DN. Please see main text for details.
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Figure 2. Biogenesis of microRNAs and their functions
MicroRNA transcripts initially originate as primary miRNAs (Pri-miRNAs) that are then
processed into Pre-miRNAs by the Drosha enzyme, which are further cleaved to result in
double-strand RNA duplexes. The miRNA duplexes are then unwound by the action of a
second enzyme, Dicer, and the mature miRNA guide strand is loaded into the RISC
complex. miRNAs in the RISC complex then guide the recognition of target RNAs to induce
their downregulation depending on the type of complementarity. Please see main text for
details. RISC, RNA-induced silencing complex; DGCR8, DiGeorge syndrome critical
region gene 8, an essential cofactor for Drosha; TRBP, transactivating response RNA-
binding protein, a cofactor for Dicer; UTR, untranslated region; P-body, processing body.
Adapted from Kato et al. [5, 21].
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